Acute Bipolar Mania

Risperdal reduces acute bipolar mania symptoms as early as day 3 of treatment

Published in Drug Week, July 2nd, 2004

Results from a controlled, large-scale, clinical trial show that when Risperdal (risperidone) was used to treat patients with acute bipolar mania, a statistically significant reduction of symptoms as compared to placebo was observed as early as the third day of treatment.

Moreover, patients in the 3-week study receiving Risperdal achieved significantly higher rates of remission as defined by a well-validated scale measuring manic symptoms. The findings appear in the June issue of The American Journal of Psychiatry.

"Bipolar disorder can be devastating. Manic behavior can cause huge problems for the patient and his or her family. The ability to...

Want to see the full article?

Purchase this article for only $3.00

We're a pay-per-view site for premium content. If you'd like to purchase this article, it's only $3.00.

Welcome to NewsRx!

Learn more about a six-week, no-risk free trial of Drug Week

Source: Drug Week (2004-07-02)

NewsRx is Social

Top Medical Newsletters

Awards

Best Health/Healthcare Content, 2012
Best Health/Healthcare Content, 2011
Best e-Business Site, 2010
Best e-Business Site, 2009
Best e-Business Site, 2008
Best e-Business Site, 2007
Best e-Business Site, 2006
Best Healthcare Content, 2005
Best Overall Internet Site, 2005
Best Interactive Site, 2005

Facts & Stats

NewsRx also is available at LexisNexis, Gale, ProQuest, Factiva, Dialog, Thomson Reuters, NewsEdge, and Dow Jones.

Google 2010 PageRank: #2 Among Top Health News and Media Publications
Google 2010 PageRank: #2 Among Top Science Publications in Biology/Physiology
Google 2010 PageRank: #2 Among Top News and Media for the Business of Pharmaceuticals
Amazon's Alexa 2010 PageRank: #2 News and Media Site for the Pharmaceutical Industry